CXCL12 Attracts Bone Marrow-Derived Cells to Uterine Leiomyomas

Area of Science:

• Gynecologic Oncology
• Stem Cell Biology
• Immunology

Background:

• Uterine leiomyomas (fibroids) are common benign tumors in women of reproductive age.
• The precise etiology and pathogenesis of uterine fibroids remain incompletely understood.
• Uterine stem/progenitor cells are implicated in fibroid development.

Purpose of the Study:

• To investigate the role of CXCL12 in recruiting bone marrow-derived cells (BMDCs) to uterine leiomyomas.
• To explore the therapeutic potential of targeting the CXCL12/CXCR4 axis in leiomyoma growth.

Main Methods:

• Analysis of CXCL12 and CXCR4 expression in leiomyoma and myometrium tissues using qRT-PCR.
• Measurement of CXCL12 protein secretion from cultured myoma cells via ELISA.
• Assessment of BMDC migration towards leiomyoma-conditioned media in vitro.
• In vivo studies using mouse models to evaluate the effect of CXCL12 on BMDC engraftment.

Main Results:

• Leiomyomas exhibited significantly higher CXCL12 expression and lower CXCR4 expression compared to normal myometrium.
• Cultured myoma cells secreted increased levels of CXCL12.
• BMDC migration was significantly enhanced towards leiomyoma-conditioned media, and this migration was blocked by a CXCR4 antagonist.
• In vivo, CXCL12 administration led to increased BMDC engraftment in mouse uterine fibroids.

Conclusions:

• CXCL12 plays a crucial role in attracting bone marrow-derived cells to uterine leiomyomas, potentially contributing to their growth.
• The CXCL12/CXCR4 signaling pathway represents a promising therapeutic target for uterine leiomyoma treatment.